We are pleased to have served as placement agent for Oruka Therapeutics' $275 million private placement. Learn more about us and all of our transactions at https://lifescicapital.com
LifeSci Capital LLC’s Post
More Relevant Posts
-
The way to win at healthcare investing is knowing the best companies BEFORE they are public. Thanks, LifeSci, for blazing the trail.
We are pleased to have served as sole and exclusive placement agent for Vyne Therapeutics' $88 million private placement. Learn more about us and all of our transactions at https://lifescicapital.com
To view or add a comment, sign in
-
-
On Tuesday we announced our first quarter 2024 financial results. On the earnings call, CEO Todd Davis, and members of the Ligand senior management team, highlighted our positive momentum during the first quarter, the significant progress of our commercial and development stage portfolio including our recent #royaltyfinancing agreement with Agenus and the launch of Pelthos Therapeutics, and the key growth drivers for the remainder of the year. View our earnings release here: https://bit.ly/4acV1D5
To view or add a comment, sign in
-
-
Pleased to show investors a new, special report by The Venture Letter™ venture stock newsletter on XORTX Therapeutics Inc. (NASDAQ & TSXV: XRTX). Strong prospects for XORTX and the company’s efforts to provide new and much-needed orphan drug therapy to slow progressive kidney disease. Biotech stocks are in a bull market right now and we see XRTX as a perfect company to investigate. Investors are invited to read our special report and take a close look at XORTX Therapeutics, now approaching its third and most important FDA drug trial. Biotech stocks are in a bull market right now and we see XRTX as a perfect company to investigate. #theventureletter #stocknews #XORTX #stocks #nasdaqlisted#stockstowatch
To view or add a comment, sign in
-
By signing up to the Argenica Therapeutics Investor Hub, you are able to stay up to date with what's going on within the business. Whether you're a shareholder, investor or someone who's interested in the development of ARG-007, receive the most up-to-date information direct to your inbox. Stay up to date with Argenica Therapeutics ➡ https://bit.ly/3UO305v #ASX #AGN #investorrelations #strokeawareness #investornews #ARG007
To view or add a comment, sign in
-
-
Look at this panel discussion webinar coming up. With experts from the likes of 4c LifeSciences, Kyowa Kirin, ADC Therapeutics, Dragonfly Therapeutics (and of course our very own Anca Copaescu). You will learn about - Importance of category management - Key criteria for vendor onboarding - Vendor evaluation workflows - Risk Management - Latest trends and innovation
Do you struggle with clinical vendor evaluation? Join the conversation will equip you with the tools and knowledge to make informed decisions in clinical vendor evaluation and management, directly impacting the success of your clinical trials. Our stellar panel will provide their insights and experiences, including Kyowa Kirin, Dragonfly Therapeutics, and 4C LifeSciences. Register today! https://lnkd.in/eMnpViuR Brenda medina Kara Titus Scott Sawicki Rob Aitchison Anca Copaescu
To view or add a comment, sign in
-
-
For anyone who has vendor management/evaluation in their remit, this webinar is "must see viewing". Great topic + Great Panel = Thought provoking ideas
Do you struggle with clinical vendor evaluation? Join the conversation will equip you with the tools and knowledge to make informed decisions in clinical vendor evaluation and management, directly impacting the success of your clinical trials. Our stellar panel will provide their insights and experiences, including Kyowa Kirin, Dragonfly Therapeutics, and 4C LifeSciences. Register today! https://lnkd.in/eMnpViuR Brenda medina Kara Titus Scott Sawicki Rob Aitchison Anca Copaescu
To view or add a comment, sign in
-
-
𝗖𝗼𝗻𝘁𝗶𝗻𝗲𝘂𝗺 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗶𝗹𝗲𝘀 𝗳𝗼𝗿 𝗜𝗣𝗢 𝘄𝗶𝘁𝗵 𝗠𝗦 𝗱𝗿𝘂𝗴 𝗶𝗻 𝗣𝗵𝗮𝘀𝗲 𝗜𝗜 Clinical-stage biotech Contineum Therapeutics, which until recently went by the name Pipeline Therapeutics, on Friday revealed plans to go public under the Nasdaq ticker $CTNM. The biotech’s drug PIPE-307 is being studied in patients with relapsing-remitting multiple sclerosis, or RRMS. It’s in Phase II, fitting the profile of IPO that investors have been seeking after two dismal years of new entrants to the market. Carmine Stengone. https://lnkd.in/e2Y_q8wS
To view or add a comment, sign in
-
Axsome Therapeutics ( $AXSM ) ACTIVELY RESPONDS TO THE MARKET with average analyst rating of BUY from 14 analysts: Axsome Therapeutics employs about 502 people. The company is managed by 21 executives with a total tenure of roughly 94 years, averaging almost 4.0 years of service per executive, having 23.9 employees per reported executive. Axsome Therapeutics reports 45.94 m gross profit. Axsome Therapeutics is selling for under 92.81. That is -0.7 percent down. Today highest was 93.88. https://lnkd.in/gde_X3yK #hotstocks #investing #trading
To view or add a comment, sign in
-
Do not miss this session at #veevasummit to learn how our Study Training product is already providing immense value to companies like Cerevel!
Less than two weeks until #VeevaSummit! I am excited to be sharing how Cerevel Therapeutics eliminated manual study training processes and improved compliance with Vault Study Training. Learn more and register here: https://bit.ly/3seOIia
To view or add a comment, sign in
-
-
If your team is using #Slack for internal IT Helpdesk Support and that experience could be improved, I have two suggestions: 1) Sign up for this Foqal webinar; and 2) contact me!!!
👉 Learn how Xilio Therapeutics runs their IT Support HelpDesk in Slack in this upcoming webinar. https://hubs.li/Q02ryVxK0 Webinar: Ditch the Slack DM Chaos: Regain Control of IT Support Join leaders from Cohere, Xilio Therapeutics, and Foqal who will share their real-world experiences in building successful Slack-powered IT help desks. April 17th @10am
To view or add a comment, sign in
-